Document is current
Any future updates will be listed below
-
Authors
Foldi, Julia https://orcid.org/0000-0002-7504-867X
Tsagianni, Anastasia
Salganik, Max
Schnabel, Catherine A.
Brufsky, Adam
van Londen, G. J.
Pusztai, Lajos
Sanft, Tara
-
Funding
Funding for this research was provided by:
BioTheranostics
- License Information
-
More Information
Article History
Received: 14 October 2022
Accepted: 22 June 2023
First Online: 30 June 2023
Declarations
:
: The study was approved by the Institutional Review Boards (IRB) at both Yale University (HIC #200030895) and the University of Pittsburgh (HCC 21–197). Given the minimal risk of the study, the IRBs determined that the study was exempt from having to obtain informed consent from patients.
: Not applicable.
: L.P. has received consulting fees and honoraria from AstraZeneca, Merck, Novartis, Bristol-Myers Squibb Genentech, Eisai, Pieris, Immunomedics, Seattle Genetics, Clovis, Syndax, H3Bio and Daiichi. A.B. has received consulting fees from AstraZeneca, Pfizer, Novartis, Lilly, Genetech/Roche, SeaGen, Daiichi Sankyo, Merck, Agendia, Sanofi and Puma; and research support from Agendia and AstraZeneca. T.S. is a consultant for Biotheranostics. The remaining authors declare no competing interests.
